



- 1) Foundation for the Accreditation of Cellular Therapy (FACT) and Joint Accreditation Committee ISCT and EBMT (JACIE). FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration. 8th Edition, December 14, 2021.

## REAGENTS

### Inspector Instructions:

	<ul style="list-style-type: none"> <li>• Reagent inventory log</li> <li>• Sampling of procedures for reagent and patient sample storage and handling</li> <li>• Sampling of typing/screening tray records for completeness</li> <li>• Validation studies for modified reagents</li> </ul>
	<ul style="list-style-type: none"> <li>• What are your laboratory's criteria for mixing components from one lot number of reagent kit with components from another lot number of kit?</li> <li>• How do you ensure that all reagents are acceptable and in date?</li> <li>• How does your laboratory manage and control reagent inventory?</li> </ul>

*Additional requirements are in the REAGENTS section of the All Common Checklist.*

#### HSC.21612 Reagent Tracking

Phase II

**The laboratory records the reagent lot numbers and shipments used for each assay.**

##### REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2004(Oct 1): 1038 [42CFR493.1256(a)]

#### HSC.21675 Reagent Kit Components

Phase II



**Combinations of reagents from different lots are checked against old reagent lots or with suitable reference material before or concurrently with being placed in service.**

##### Evidence of Compliance:

- ✓ Records of checks performed on combinations of reagents from different lots

**\*\*REVISED\*\* 12/26/2024**

#### HSC.21800 Reagent and Specimen Storage

Phase II



**Optimal storage conditions for reagent and specific types of patient specimens are defined and followed.**

*NOTE 1: Written procedures must include storage and retention requirements for specific types of patient specimens, including lymphocytes, RNA, DNA, and sera.*

*NOTE 2: Use of continuous monitoring and alert systems and back-up storage plans must be specified as applicable.*

##### Evidence of Compliance:

- ✓ Records of storage and retention at defined conditions

##### REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2023(Dec 28):[42CFR493.1278(a)(1) and (a)(2)].